{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:49:02Z","timestamp":1758361742501,"version":"3.44.0"},"reference-count":38,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2025,8,31]]},"DOI":"10.5582\/ddt.2025.01044","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T22:07:51Z","timestamp":1755814071000},"page":"253-261","source":"Crossref","is-referenced-by-count":0,"title":["Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments"],"prefix":"10.5582","volume":"19","author":[{"given":"Toshimasa","family":"Shimizu","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Naga-saki University Graduate School of Biomedical Sciences, Nagasaki, Japan."},{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ya","family":"Kawashiri","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Naga-saki University Graduate School of Biomedical Sciences, Nagasaki, Japan."},{"name":"Department of Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Naga-saki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Kiya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Morita","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Sato","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yano","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tobata General Hospital, Kitakyushu, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamami","family":"Yoshitama","sequence":"additional","affiliation":[{"name":"Yoshitama Clinic for Rheumatic Diseases, Kagoshima, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hakujyujikai Sasebo Chuo Hospital, Sasebo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Eiraku","sequence":"additional","affiliation":[{"name":"Eiraku Internal Medicine Clinic, Kagoshima, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Okano","sequence":"additional","affiliation":[{"name":"Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ushio","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Kagawa University Hospital, Kagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Kagawa University Hospital, Kagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Itami","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nozaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Naga-saki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376:1094-1108.","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Smolen JS, Breedveld FC, Burmester GR, <i>et al.<\/i> Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75:3-15.","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, Fautrel B, van Vollenhoven R. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016; 75:1428-1437.","DOI":"10.1136\/annrheumdis-2016-209201"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004; 50:3432-3443.","DOI":"10.1002\/art.20568"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343:1594-1602.","DOI":"10.1056\/NEJM200011303432202"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, Takeuchi T. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007; 17:28-32.","DOI":"10.1007\/s10165-006-0532-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Saito K, Ohtsubo H, Lee SJ, Nambu Y. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015; 25:817-824.","DOI":"10.3109\/14397595.2015.1022297"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mork C, Jahnsen J, Kvien TK. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017; 389:2304-2316.","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, Lee SJ, Nambu Y. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017; 27:237-245.","DOI":"10.1080\/14397595.2016.1206244"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Colebatch AN, Edwards CJ, Ostergaard M, <i>et al<\/i>. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013; 72:804-814.","DOI":"10.1136\/annrheumdis-2012-203158"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. D&apos;Agostino MA, Terslev L, Wakefield R, \u00d8stergaard M, Balint P, Naredo E, Iagnocco A, Backhaus M, Grassi W, Emery P. Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission. Ann Rheum Dis. 2016; 75:1902-1908.","DOI":"10.1136\/annrheumdis-2016-209646"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Naredo E, Moller I, Cruz A, Carmona L, Garrido J. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2008; 58:2248-2256.","DOI":"10.1002\/art.23682"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kawashiri SY, Nishino A, Shimizu T, <i>et al.<\/i> Ultrasound disease activity of bilateral wrist and finger joints at three months reflects the clinical response at six months of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs. Mod Rheumatol. 2017; 27:252-256.","DOI":"10.1080\/14397595.2016.1221874"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, Constantin A, Foltz V, Cantagrel A. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014; 53:2110-2118.","DOI":"10.1093\/rheumatology\/keu217"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kawashiri SY, Suzuki T, Nakashima Y, Horai Y, Okada A, Iwamoto N, Ichinose K, Tamai M, Arima K, Nakamura H, Origuchi T, Uetani M, Aoyagi K, Eguchi K, Kawakami A. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion. Rheumatology (Oxford). 2014; 53:562-569.","DOI":"10.1093\/rheumatology\/ket405"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research in-volving human subjects. JAMA. 2013; 310:2191-2194.","DOI":"10.1001\/jama.2013.281053"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kawashiri SY, Shimizu T, Sato S, Morimoto S, Kawazoe Y, Sumiyoshi R, Hosogaya N, Fukushima C, Yamamoto H, Kawakami A. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments. Medicine (Baltimore). 2020; 99:e21151.","DOI":"10.1097\/MD.0000000000021151"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Aletaha D, Neogi T, Silman AJ, <i>et al.<\/i> 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62:2569-2581.","DOI":"10.1002\/art.27584"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Prevoo ML, van &apos;t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38:44-48.","DOI":"10.1002\/art.1780380107"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23:137-145.","DOI":"10.1002\/art.1780230202"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Torp-Pedersen ST, Terslev L. Settings and artefacts relevant in colour\/power Doppler ultrasound in rheumatology. Ann Rheum Dis. 2008; 67:143-149.","DOI":"10.1136\/ard.2007.078451"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. D&apos;Agostino MA, Boers M, Wakefield RJ, Berner Hammer H, Vittecoq O, Filippou G, Balint P, M\u00f6ller I, Iagnocco A, Naredo E, \u00d8stergaard M, Gaillez C, Le Bars M. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. RMD Open. 2016; 2:e000237.","DOI":"10.1136\/rmdopen-2015-000237"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Terslev L, Naredo E, Aegerter P, Wakefield RJ, Backhaus M, Balint P, Bruyn GAW, Iagnocco A, Jousse-Joulin S, Schmidt WA, Szkudlarek M, Conaghan PG, Filippucci E, D&apos;Agostino MA. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system. RMD Open. 2017; 3:e000427.","DOI":"10.1136\/rmdopen-2016-000427"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tanaka Y, Oba K, Koike T, <i>et al<\/i>. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Ann Rheum Dis. 2020; 79:94-102.","DOI":"10.1136\/annrheumdis-2019-216169"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. van der Heijde D. How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol. 2000; 27:261-263.","DOI":"10.1097\/00002281-200007000-00005"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, Euller-Ziegler L. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint bone spine. 2009; 76:350-355.","DOI":"10.1016\/j.jbspin.2008.11.009"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Nishino A, Kawashiri SY, Koga T, <i>et al.<\/i> Ultrasonographic efficacy of biologic and targeted synthetic disease-modifying antirheumatic drug therapy in rheumatoid arthritis from a multicenter rheumatoid arthritis ultrasound prospective cohort in Japan. Arthritis Care Res. 2018; 70:1719-1726.","DOI":"10.1002\/acr.23551"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kuek A, Hazleman BL, Ost\u00f6r AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007; 83:251-260.","DOI":"10.1136\/pgmj.2006.052688"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev. 2013; 12:835-838.","DOI":"10.1016\/j.autrev.2012.11.009"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yoo DH, Prodanovic N, Jaworski J, <i>et al.<\/i> Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017; 76:355-363.","DOI":"10.1136\/annrheumdis-2015-208786"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. D\u00f6rner T, Strand V, Cornes P, Gon\u00e7alves J, Gul\u00e1csi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016; 75:974-982.","DOI":"10.1136\/annrheumdis-2016-209166"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Glintborg B, Loft AG, Omerovic E, <i>et al<\/i>. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019; 78:192-200.","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Colloca L, Panaccione R, Murphy TK. The Clinical Implications of Nocebo Effects for Biosimilar Therapy. Front Pharmacol. 2019; 10:1372.","DOI":"10.3389\/fphar.2019.01372"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Yoo DH, Hrycaj P, Miranda P, <i>et al<\/i>. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72:1613-1620.","DOI":"10.1136\/annrheumdis-2012-203090"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, Abud-Mendoza C, Navarra S, Kadinov V, Sariego IG, Hong SS, Lee SY, Park W. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016; 18:82.","DOI":"10.1186\/s13075-016-0981-6"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Glintborg B, S\u00f8rensen IJ, Loft AG, <i>et al.<\/i> A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017; 76:1426-1431.","DOI":"10.1136\/annrheumdis-2016-210742"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388:2023-2038.","DOI":"10.1016\/S0140-6736(16)30173-8"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, <i>et al.<\/i> Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLoS One. 2018; 13:e0192425.","DOI":"10.1371\/journal.pone.0192425"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/4\/19_2025.01044\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:23:17Z","timestamp":1758342197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/4\/19_2025.01044\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01044","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"type":"print","value":"1881-7831"},{"type":"electronic","value":"1881-784X"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"article-number":"2025.01044"}}